EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exosome Proteomics of SOD1 D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker

Mukesh Gautam, Ali Laith, Aslihan Gunel, Melda Yilmaz, Nazli Basak iD, Halil Idrisoglu, P Hande Ozdinler iD

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Mukesh Gautam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Exosomes, Superoxide Dismutase-1, Fibronectins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: A Long Swim, Les Turner ALS Foundation, The Queen B Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease. Super oxide dismutase 1 ( SOD1 ) gene mutations cause ALS, and the D90A mutation is associated with primarily upper motor neuron (UMN) loss.

Objective

Our goal is to reveal the early cellular events in ALS pathology and identify potential pharmacokinetic biomarkers, using well‐defined patient populations.

Methods

Exosomes are isolated from serum either single or multiple time points from members of one family, who have SOD1 D90A mutation, and their protein content is assessed by tandem mass‐spec proteomics. Ingenuity Pathway analysis is used to highlight cellular events that are perturbed as the disease progressed. The linear regression analysis, using ALSFRS scores of patients and the protein content, helps identify potential pharmacokinetic biomarkers, which are confirmed with the ELISA assay.

Results

Father, Son, and Daughter are at different disease stages and carry the SOD1 D90A mutation. Albeit, the Daughter remained asymptomatic within a year; she had significant biological changes. The Son transitioned from asymptomatic to early symptomatic within a year, while the Father was symptomatic. Patient #2, who also had the SOD1 D90A mutation, was more advanced. Comparison of the Son, Father, and Patient #2 suggested Fibronectin1 (FN1) as a potential pharmacokinetic biomarker, which is confirmed by ELISA.

Interpretation

Exosome proteomics offer a powerful approach to interrogate disease‐specific or disease‐related proteins that become present in the blood. This helps define the perturbed cellular events with respect to disease progression and reveal potential pharmacokinetic biomarkers. We find FN1 levels to increase with disease progression, suggesting it may be a pharmacokinetic biomarker, especially for ALS patients with prominent UMN loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisExosomesSuperoxide Dismutase-1FibronectinsHumansBiomarkersProteomicsMaleFemaleMutationMiddle AgedDisease ProgressionAdult

Stichwörter der Autor:innen

ALSSOD1biomarkerexosomesproteomics

Substanzen

Superoxide Dismutase-1BiomarkersSOD1 protein, humanFibronectinsFN1 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Department of Chemistry and Biochemistry, Kirsehir Ahi Evran University, Kirsehir, Turkiye.
  • Medical Sciences Department, Kocaeli University, Izmit, Turkiye.
  • School of Medicine, KUTTAM-NDAL, Koc University, Istanbul, Turkiye.
  • School of Medicine, Department of Neurology, Istanbul University, Istanbul, Turkiye.
  • Feinberg School of Medicine, Les Turner ALS Center, Northwestern University, Chicago, Illinois, USA.

ORCID-Profile: Nazli Basak, P Hande Ozdinler

Förderung

  • A Long Swim
  • Les Turner ALS Foundation
  • The Queen B Foundation

Zitieren

APA

Gautam, M., Laith, A., Gunel, A., Yilmaz, M., Basak, N., Idrisoglu, H., & Ozdinler, P. H. (2026). Exosome Proteomics of SOD1 D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70208

Vancouver

Gautam M, Laith A, Gunel A, Yilmaz M, Basak N, Idrisoglu H, et al. Exosome Proteomics of SOD1 D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70208

BibTeX
@article{Gautam2026,
  author = {Gautam, Mukesh and Laith, Ali and Gunel, Aslihan and Yilmaz, Melda and Basak, Nazli and Idrisoglu, Halil and Ozdinler, P Hande},
  title = {Exosome Proteomics of SOD1 D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70208}
}
Kostenlos starten →